Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Ublituximab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ublituximab, an antibody targeting CD20.
6 min read
Ocrelizumab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ocrelizumab, an antibody targeting CD20.
6 min read
Ofatumumab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ofatumumab, an antibody targeting CD20.
Latest Hotspot
8 min read
CTR20261743 Isosulfan Blue Chylous Ascites Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261743 clinical trial report covering Isosulfan Blue, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Obinutuzumab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obinutuzumab, an antibody targeting CD20.
Latest Hotspot
8 min read
ChiCTR2600124230 iPSC derived cardiac muscle cell (Help Therapeutics) Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600124230 clinical trial report covering iPSC derived cardiac muscle cell (Help Therapeutics), Phase 3, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
CTR20261782 Cenerimod Lupus Nephritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261782 clinical trial report covering Cenerimod, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Rituximab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rituximab, an antibody targeting CD20.
Latest Hotspot
8 min read
ChiCTR2600124390 Warfarin Potassium Thrombosis of cerebral veins Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600124390 clinical trial report covering Warfarin Potassium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07577843 Guselkumab/Golimumab Crohn Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577843 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07577856 Guselkumab/Golimumab Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577856 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261803 Savolitinib c-Met positive Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261803 clinical trial report covering Savolitinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.